HBM Holdings enters license agreement with Visterra

HBM Holdings Limited (HKEX: 2142) announced that its wholly-owned subsidiary, Nona Biosciences US, Inc., has entered into a license agreement with Visterra, Inc. The partnership aims to leverage Nona Biosciences' Harbour Mice® technology platform, specifically its heavy-chain-only antibody (HCAb) capabilities, to develop Visterra's next-generation biotherapeutic pipeline targeting immune-mediated and autoimmune diseases. The Harbour Mice® platform offers advantages such as reduced immunogenicity, making it suitable for next-generation biotherapeutics. Nona Biosciences, known for its integrated solutions "Idea to IND," will contribute its expertise in target validation and antibody discovery. Visterra, a biologics research company, will use the partnership to develop therapies for immune-mediated kidney diseases.